GURUFOCUS.COM » STOCK LIST » Basic Materials » Chemicals » BioNexus Gene Lab Corp (NAS:BGLC) » Definitions » Price-to-Free-Cash-Flow

BGLC (BioNexus Gene Lab) Price-to-Free-Cash-Flow : N/A (As of Dec. 13, 2024)


View and export this data going back to 2020. Start your Free Trial

What is BioNexus Gene Lab Price-to-Free-Cash-Flow?

As of today (2024-12-13), BioNexus Gene Lab's share price is $0.271. BioNexus Gene Lab's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Sep. 2024 was $-0.15. Hence, BioNexus Gene Lab's Price-to-Free-Cash-Flow Ratio for today is N/A.

The historical rank and industry rank for BioNexus Gene Lab's Price-to-Free-Cash-Flow or its related term are showing as below:

During the past 6 years, BioNexus Gene Lab's highest Price-to-Free-Cash-Flow Ratio was 25560.00. The lowest was 20.24. And the median was 304.00.

BGLC's Price-to-Free-Cash-Flow is not ranked *
in the Chemicals industry.
Industry Median: 20.48
* Ranked among companies with meaningful Price-to-Free-Cash-Flow only.

BioNexus Gene Lab's Free Cash Flow per Share for the three months ended in Sep. 2024 was $-0.09. Its Free Cash Flow per Share for the trailing twelve months (TTM) ended in was $-0.15.


BioNexus Gene Lab Price-to-Free-Cash-Flow Historical Data

The historical data trend for BioNexus Gene Lab's Price-to-Free-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioNexus Gene Lab Price-to-Free-Cash-Flow Chart

BioNexus Gene Lab Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Price-to-Free-Cash-Flow
Get a 7-Day Free Trial - 1,840.00 - 325.71 -

BioNexus Gene Lab Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Price-to-Free-Cash-Flow Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of BioNexus Gene Lab's Price-to-Free-Cash-Flow

For the Specialty Chemicals subindustry, BioNexus Gene Lab's Price-to-Free-Cash-Flow, along with its competitors' market caps and Price-to-Free-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BioNexus Gene Lab's Price-to-Free-Cash-Flow Distribution in the Chemicals Industry

For the Chemicals industry and Basic Materials sector, BioNexus Gene Lab's Price-to-Free-Cash-Flow distribution charts can be found below:

* The bar in red indicates where BioNexus Gene Lab's Price-to-Free-Cash-Flow falls into.



BioNexus Gene Lab Price-to-Free-Cash-Flow Calculation

BioNexus Gene Lab's Price-to-Free-Cash-Flow ratio for today is calculated as

Price-to-Free-Cash-Flow Ratio=Share Price/ Free Cash Flow per Share (TTM)
=0.271/-0.148
=N/A

BioNexus Gene Lab's Share Price of today is $0.271.
BioNexus Gene Lab's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.15.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

Price-to-Free-Cash-Flow Ratio=Market Cap/Free Cash Flow

BioNexus Gene Lab  (NAS:BGLC) Price-to-Free-Cash-Flow Explanation

Free Cash Flow is considered more important than earnings by value investors. The reason is because, in principle, only the net cash that can be taken from the business belongs to shareholders. This Free Cash Flow can be used to grow the business, reduce debt or return to shareholders in dividends or share buybacks.

In a DCF Calculation Free Cash Flow is used to determine the intrinsic value of companies.


Be Aware

In real business, Free Cash Flow can be affected by the change in accounts receivable, accounts payable, management's decision on expansion, etc. Therefore, investors should look at the Free Cash Flow over the longer term. Long-term average of Free Cash Flow is a more reliable indicator for real free cash flow.


BioNexus Gene Lab Price-to-Free-Cash-Flow Related Terms

Thank you for viewing the detailed overview of BioNexus Gene Lab's Price-to-Free-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.


BioNexus Gene Lab Business Description

Traded in Other Exchanges
N/A
Address
No. 8 Jalan Kerinchi, The Vertical Business Suite II, Unit 02, Level 10, Tower B, Avenue 3, Bangar South, Kuala Lumpur, SGR, MYS, 59200
BioNexus Gene Lab Corp through its wholly owned subsidiary, focuses on the sale of chemical raw materials for the manufacture of industrial, medical, appliance, aero, automotive, mechanical, and electronic industries in the Southeast Asia region. These countries include Malaysia, Indonesia, Vietnam, and other countries in Southeast Asia. In addition, the Company is in the business of developing and providing safe, effective, and non-invasive liquid biopsy tests for the early detection of biomarkers that it believes are linked to diseases to minimize treatment costs and improve patient management. Its non-invasive blood tests provide analysis of changes in RNA to detect the potential risk of 11 different diseases.
Executives
Chak Hua Yew director 1 COMMONWEALTH LANE #08-22, SINGAPORE U0 149544
Yeat Min Fong director 10-2 TOWER B, VERTICAL BUSINESS SUITE, 8 JALAN KERINCHI, KUALA LUMPUR N8 59200
Teng Fook Fong director 10-2 TOWER B, VERTICAL BUSINESS SUITE, 8 JALAN KERINCHI, KUALA LUMPUR N8 59200
Chee Keong Yap director 10-2 TOWER B, VERTICAL BUSINESS SUITE, 8 JALAN KERINCHI, KUALA LUMPUR N8 59200
Boon Teong Teoh director 10-2 TOWER B, VERTICAL BUSINESS SUITE, 8 JALAN KERINCHI, KUALA LUMPUR N8 59200
Yee Meng Wong director, officer: President 10-2 TOWER B, VERTICAL BUSINESS SUITE, 8 JALAN KERINCHI, KUALA LUMPUR N8 59200
Wei Li Leong officer: Chief Financial Officer 10-2 TOWER B, VERTICAL BUSINESS SUITE, 8 JALAN KERINCHI, KUALA LUMPUR N8 59200
Chai Ping Lin director 10-2 TOWER B, VERTICAL BUSINESS SUITE, 8 JALAN KERINCHI, KUALA LUMPUR N8 59200
Tai Tan Liong director, officer: Chief Operating Officer 10-2 TOWER B, VERTICAL BUSINESS SUITE, 8 JALAN KERINCHI, KUALA LUMPUR N8 59200
Sook Keng Yeoh director, officer: Chief Executive Officer 10-2 TOWER B, VERTICAL BUSINESS SUITE, 8 JALAN KERINCHI, KUALA LUMPUR N8 59200

BioNexus Gene Lab Headlines

From GuruFocus